Nautilus Biotechnology
51 articles about Nautilus Biotechnology
-
Nautilus Biotechnology Reports Second Quarter 2021 Financial Results
8/10/2021
Nautilus Biotechnology, Inc., a life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome, reported financial results for the second quarter ended June 30, 2021.
-
Nautilus Biotechnology Appoints Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development
8/9/2021
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the appointment of Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development.
-
Nautilus Biotechnology to Announce Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021
7/13/2021
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter of fiscal year 2021 before market open on Tuesday, August 10th, 2021.
-
Nautilus Biotechnology Appoints Emma Lundberg, Ph.D., to Scientific Advisory Board
6/17/2021
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the appointment of Emma Lundberg, Ph.D. to its Scientific Advisory Board.
-
Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome
6/10/2021
Nautilus Biotechnology, Inc. announced the completion of its business combination with Arya Sciences Acquisition Corp III, a special purpose acquisition company sponsored by Perceptive Advisors.
-
Nautilus to Present at Goldman Sachs 42nd Annual Global Healthcare Conference
5/27/2021
Nautilus Biotechnology, Inc. (“Nautilus Biotechnology” or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating in the upcoming Goldman Sachs 42nd Annual Global Healthcare Conference. Nautilus’ management is scheduled to present on Thursday, June 10th at 3:00 p.m. Eastern Time/12:00 p.m. Pacific Time.
-
Nautilus Biotechnology Appoints Matt Murphy as General Counsel
4/6/2021
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the appointment of Matt Murphy, Esq., as General Counsel.
-
Money on the Move: February 3-9
2/10/2021
The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients. -
According to NASDAQ, SPACs – Special Purpose Acquisition Companies – now make up more than a third of all IPOs.
-
Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III
2/8/2021
Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III (Nasdaq: ARYA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol “NAUT” Nautilus Biotechnology is expected to receive $350 million in proceeds through the business combination, including a $200 million fully committed PIPE led by Perceptive Advisors and other top-tier healthcare investors
-
Nautilus Biotechnology Expands Executive Team
1/5/2021
Proven leaders in product, finance, and marketing to accelerate the development of Nautilus’ next-generation, single-molecule proteomics analysis platform